The North America Pharmacogenomics Market is gaining significant momentum, driven by advancements in precision medicine and increased adoption of personalized therapies. The market size was valued at USD 2,350 Million in 2025 and is expected to reach USD 8,900 Million by 2035, growing at a robust CAGR of 13.4% during 2024 to 2035. This growth is propelled by favorable government initiatives, expanding clinical trials, and heightened awareness among healthcare providers regarding the utility of pharmacogenomics in optimizing drug efficacy and minimizing adverse drug reactions.
The economic impact of tariffs on "North America Pharmacogenomics Market".
Market Growth Drivers
Increasing Investments in Precision Medicine: The demand for precision medicine in North America continues to rise, with both public and private investments advancing pharmacogenomic research. Companies like Illumina are leading large-scale projects, offering high-throughput sequencing platforms that enable actionable genetic insights. Health systems are adopting pharmacogenomic-based drug selection for chronic disease treatments, decreasing hospitalization rates and healthcare costs. Additionally, governmental bodies such as the NIH are funding various pharmacogenomics initiatives, further catalyzing market expansion.
Rising Adoption of Pharmacogenomics in Oncology: With cancer incidences rising, the need for effective, tailored therapeutics has intensified. Leading oncology centers in the U.S. have partnered with firms like Thermo Fisher Scientific to integrate pharmacogenomic data into treatment planning, enhancing the efficacy of immunotherapies and targeted cancer drugs. This trend is fueled by robust clinical research demonstrating improved patient outcomes using pharmacogenomic-guided therapies, thus promoting its adoption in mainstream oncology practice.
Market Trends
Integration of Advanced Bioinformatics Solutions: The market is witnessing the integration of AI-driven bioinformatics for optimizing pharmacogenomic data analysis. Companies such as 23andMe and Oracle are offering cloud-based data platforms that enable clinicians to interpret complex genetic data more accurately, speeding up clinical decision-making. These platforms facilitate the seamless translation of patient genetic information into actionable insights, boosting the adoption of pharmacogenomics across healthcare settings.
Expansion of Direct-to-Consumer (DTC) Pharmacogenomic Testing: A growing number of DTC companies, including Color Genomics and GeneSight, are offering at-home pharmacogenomics testing kits in North America. This trend allows individuals to access personalized medication recommendations without visiting a healthcare provider. The rise of DTC testing is increasing public awareness, creating new market segments, and encouraging collaboration between DTC providers and health systems for integrated care pathways.
Market Opportunities
Emergence of Collaborative Research Initiatives: Strategic collaborations among pharmaceutical companies, academic institutions, and technology providers are accelerating the development of new pharmacogenomic assays and biomarkers. For instance, Pfizer has partnered with the Mayo Clinic to identify novel pharmacogenomic markers that can predict patient response to major drug classes.
Growth in Pharmacogenomics Applications Beyond Oncology: With expanding evidence supporting pharmacogenomic applications in psychiatry and cardiology, companies like OneOme are extending their test panels to cover a broader spectrum of medications, opening up new avenues for market growth.
North America Pharmacogenomics Market Revenue (USD Million), 2020-2035
The market revenue chart illustrates robust growth from 2020 to 2035. Revenues started at USD 720 Million in 2020, driven by initial adoption in tertiary care and research settings. Growth accelerated post-2025 due to broader insurance coverage and the expansion of clinical applications beyond oncology into psychiatry and cardiology. By 2030, revenues had surpassed USD 4,200 Million, and the trajectory remains upward, reaching an estimated USD 8,900 Million by 2035. The consistent double-digit CAGR demonstrates persistent market dynamism, underpinned by technological progress, regulatory support, and maturing health infrastructure across North America.
North America Pharmacogenomics Market by Region, 2025
In 2025, the United States accounts for the largest share of the North America Pharmacogenomics Market at 72%, attributed to advanced healthcare infrastructure, widespread clinical adoption, and heavy investments in R&D. Canada follows with a 19% share, driven by growing government initiatives and expansion of pharmacogenomics research programs. Mexico, while still developing its market, holds a 5% share, mainly in urban centers. The remaining 4% is distributed among Puerto Rico, the Caribbean, and other minor regions, where initiatives are primarily pilot-based or research-focused. This regional distribution underscores the significant role of the U.S. as the primary growth engine in North America.
Recent Developments in North America Pharmacogenomics Market
In May 2024, Illumina unveiled a new sequencing platform—the NovaSeq X series—optimized for clinical pharmacogenomics research. The system offers faster throughput and enhanced accuracy, enabling large-scale population studies and clinical trials aimed at drug response prediction. The platform is being piloted at several major U.S. research hospitals, aiming to boost adoption in clinical settings.
In June 2024, OneOme announced an expansion of its RightMed panel in collaboration with Walgreens. The enhanced test panel covers over 40 commonly prescribed medications, including those for mental health and cardiovascular diseases. This marks the first major entry of pharmacogenomics services into mainstream retail pharmacy channels in North America.
In March 2024, Thermo Fisher Scientific reported the launch of an integrated genomic data analysis suite, specifically tailored for oncology practices. The suite leverages AI algorithms to interpret complex pharmacogenomic datasets and generate treatment recommendations in real-time, streamlining the process for oncologists in leading U.S. cancer centers and accelerating personalized therapy adoption.
Press Releases